Company intelligence / Profile preview

CS Diagnostics

Ownership: Private
Employees: ~1
Development stage: Commercial

Overview

CS Diagnostics has commercialized medical devices including injectors, hose systems, PCR tests, medicines, gloves, and two flagship products—CS Protect-Hydrogel (a next-generation organ spacer with broader applications than SpaceOAR) and MEDUSA (a smart disinfectant product). The company is expanding globally with a focus on regulatory approvals such as U.S. FDA/EPA for its new products. It conducts post-market studies to ensure safety and efficacy.

Therapeutic areas: OncologyInfectious Diseases
Modalities: DeviceHydrogel-based drug delivery therapy
Industry: Molecular Diagnostics

Drug pipeline

2 assets

CS-Protect Hydrogel

Commercial

Indications: Disinfection

1 more asset in the full pipeline.

Request access →

Partnerships

La Pharm GmbH – exclusive distributorship agreement for Hydrogel in the U.S.

Beyond the preview

Go deeper on CS Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CS Diagnostics.

Explore the full profile